{"id":"W2915544780","doi":"10.3747/co.26.4116","title":"Canadian Consensus: Oligoprogressive, Pseudoprogressive, and Oligometastatic Non-Small-Cell Lung Cancer","year":2019,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; Centre Hospitalier de l’Université de Montréal; Alberta Cancer Foundation; McGill University Health Centre; BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Hospital; University of Manitoba; CancerCare Manitoba; University of Ottawa","funders":"Pfizer Canada; Bristol-Myers Squibb Canada; EMD Serono; Siemens Healthineers; AstraZeneca Canada; Varian Medical Systems; Sanofi; Amgen; Pfizer; Celgene; Health Research; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Merck Canada; Accuray","keywords":"Medicine; Clinical trial; Clinical Practice; Best practice; Medical physics; MEDLINE; Intensive care medicine; Consensus conference; Lung cancer; Quality of life (healthcare); Family medicine; Oncology; Pathology; Nursing; Internal medicine","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":true,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.04783233,0.00110621,0.001631876,0.004475649,0.006322568,0.005466855,0.005274174,0.01164057,0.008619671],"category_scores_gemma":[0.09727647,0.0007362844,0.002180407,0.004145552,0.004786223,0.003394034,0.00636655,0.01090861,0.002440477],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.03930749,"about_ca_system_score_gemma":0.17191,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.284211,"about_ca_topic_score_gemma":0.3898495,"domain_scores_codex":[0.961924,0.01352896,0.008397209,0.002250027,0.01068346,0.003216405],"domain_scores_gemma":[0.8938859,0.01552721,0.006927482,0.001704781,0.0679707,0.01398395],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001498343,0.00005466865,0.002883243,0.007910443,0.0001375141,0.001149613,0.003385775,0.0009947673,0.000788201,0.01493641,0.7975466,0.1700628],"study_design_scores_gemma":[0.0001325099,0.00005433944,0.003204837,0.01746386,0.0001562589,0.001334265,0.003728167,0.0005489455,0.000349564,0.01629281,0.9565645,0.0001699545],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"review","genre_scores_codex":[0.003360413,0.077039,0.007185802,0.824773,0.02617121,0.00164793,0.001875247,0.0001289815,0.05781839],"genre_scores_gemma":[0.2280459,0.1896528,0.1093318,0.3848079,0.01549029,0.003841233,0.008511509,0.0003154559,0.06000315],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.715789,"threshold_uncertainty_score":0.5651134,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0325985276429622,"score_gpt":0.403185643526607,"score_spread":0.3705871158836448,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}